Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13681563 | 0.91 | GABRA1 (0.53) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL13681556 | 0.87 | GABRA1 (0.43) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL13681475 | 0.85 | GABRA1 (0.47) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL13681534 | 0.82 | GABRA1 (0.45) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL13681526 | 0.77 | GABRA1 (0.47) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL13681571 | 0.77 | PDE4A (0.49) | GABRA1GABRG2GABRB3GABRB2PDE4A | |
| SCHEMBL12311024 | 0.77 | GABRA1 (0.45) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL17873493 | 0.77 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL12311028 | 0.77 | GABRA1 (0.45) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL17873491 | 0.77 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRB2GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585861-B2 | HIV replication inhibitors; for (multi)drug resistant HIV infection | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-09-08 | — | — | US | disclosed |
| US-20070037811-A1 | HIV replication inhibitors; for (multi)drug resistant HIV infection | BMO BANK N.A., AS ADMINISTRATIVE AGENT | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037811-A1 | HIV replication inhibitors; for (multi)drug resistant HIV infection | REV1, CCNI, MCM6 | GABRA1 4012/4885GABRG2 4088/4885GABRB3 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.